Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation
- Market cap
- $4.61B
Your view on ADPT
Overview
What the company does, where it operates, and who runs it.
About Adaptive Biotechnologies Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chad M. Robins
- Headquarters
- 1165 Eastlake Avenue East, Seattle, WA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chad M. Robins
- Headquarters
- 1165 Eastlake Avenue East, Seattle, WA, US
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.
It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.
In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications.
Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Adaptive Biotechnologies Corporation. Starting points for Adaptive Biotechnologies Corporation: EPS -$0.44, beta 2.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Adaptive Biotechnologies Corporation. Trailing twelve-month EPS for Adaptive Biotechnologies Corporation stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
6 firms, last 12 months- Strong Buy0
- Buy5
- Hold1
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.03 | −$0.06 | −$0.39 | −$0.07 |
| Lowest estimate | −$0.04 | −$0.08 | −$0.40 | −$0.11 |
| Highest estimate | −$0.03 | −$0.05 | −$0.37 | $0.05 |
| Number of analysts | 3 | 3 | 4 | 4 |
| A year ago | −$0.091 | −$0.13 | −$0.391 | — |
| Growth vs a year ago | — | +50.5% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $80.55M | $80.56M | $307.00M | $374.36M |
| Lowest estimate | $79.23M | $79.62M | $305.73M | $370.51M |
| Highest estimate | $82.76M | $82.31M | $309.20M | $381.03M |
| Number of analysts | 6 | 5 | 6 | 6 |
| A year ago | $71.68M | $70.87M | $276.98M | — |
| Growth vs a year ago | +12.4% | +13.7% | +10.8% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Adaptive Biotechnologies Corporation. Adaptive Biotechnologies Corporation has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ELTXElicio Therapeutics, Inc. | Healthcare | NASDAQ | $30.3M | ||
| ELUTElutia Inc. | Healthcare | NASDAQ | $36.8M | ||
| ELVNEnliven Therapeutics, Inc. | Healthcare | NASDAQ | $3.3B | ||
| EMMAEmmaus Life Sciences, Inc. | Healthcare | OTC | $894,118 | ||
| ENDVEndonovo Therapeutics, Inc. | Healthcare | OTC | $31,875 | ||
| ENGNenGene Holdings Inc. | Healthcare | NASDAQ | $124.0M | ||
| ENGNWenGene Holdings Inc. Warrants | Healthcare | NASDAQ | $9.2M | ||
| ENLVEnlivex Therapeutics Ltd. | Healthcare | NASDAQ | $20.2M | ||
| ENP.AXEntropy Neurodynamics Limited | Healthcare | ASX | — | ||
| ENSCEnsysce Biosciences, Inc. | Healthcare | NASDAQ | $7.2M | ||
| ENTAEnanta Pharmaceuticals, Inc. | Healthcare | NASDAQ | $239.7M | ||
| ENTXEntera Bio Ltd. | Healthcare | NASDAQ | $567.7M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.16% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.01% | |
| ARKGARK Genomic Revolution ETF | $2.2B in assets | 2.88% | |
| VBVanguard Small-Cap ETF | $76.9B in assets | 0.02% | |
| HELXFranklin Genomic Advancements ETF | $33M in assets | 5.10% | |
| HTECROBO Global Healthcare Technology and Innovation ETF | $110M in assets | 2.05% | |
| TMATMain Thematic Innovation ETF | $212M in assets | 1.56% | |
| DWASInvesco Dorsey Wright SmallCap Momentum ETF | $376M in assets | 1.43% | |
Largest holders first, then the funds most concentrated in ADPT.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Adaptive Biotechnologies Corporation, and how their positions are changing. At a $4.61B market value, institutional positions materially move Adaptive Biotechnologies Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Adaptive Biotechnologies Corporation executives and directors. Shares of Adaptive Biotechnologies Corporation have traded between $4.27 and $17.89 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Adaptive Biotechnologies Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Adaptive Biotechnologies Corporation. Coverage tracks Adaptive Biotechnologies Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Adaptive Biotechnologies Corporation.